Abu Dhabi: The Ministry of Well being and Prevention (MoHAP), in collaboration with the Division of Well being – Abu Dhabi (DoH) and Dubai Well being Authority (DHA), has introduced the remedy outcomes for anti-viral medication Sotrovimab in treating delicate to average COVID-19 circumstances amongst high-risk sufferers together with adults, pregnant ladies and kids aged 12 and above who’re susceptible to progressing to extreme signs and meet different related standards.
The MoHAP has accepted using Sotrovimab, which is produced by international biopharmaceutical firm GlaxoSmithKline (GSK), after conducting native analysis. It has additionally been accepted for emergency use by the US Meals and Drug Administration.
Between 30 June and 13 July, Sotrovimab was administered to six,175 sufferers with COVID-19 in Abu Dhabi. About 52 per cent of the sufferers had been aged 50 or above, and virtually all recipients had a number of comorbidities together with weight problems, most cancers, heart problems and diabetes.
97 % of recipients absolutely recovered inside 14 days. The remedy additionally resulted in 100% prevention of loss of life amongst recipients and 99 % prevention of admission to ICU.
Sotrovimab is a monoclonal antibody remedy delivered via intravenous remedy in accordance with protocols developed by the Nationwide Scientific Committee.
The UAE was one of many first nations on this planet to obtain a cargo of Sotrovimab in mid-June, following an settlement between the Division of Well being – Abu Dhabi, Rafed, a number one group buying organisation, GSK and Etihad Cargo.